Dr. Georgios V. Georgakis 

Surgical Oncologist
S.U.N.Y Stony Brook
Stony Brook, NY 11794
View Contact Information

Schedule a Conversation with a HIPEC Surgeon

The surgeon or staff member will make their best effort to call you at your requested time. If they become unavailable you will receive a text.

Fill out my online form.

Board Certified

Board certification by an ABMS Member Board is the premier, independently assessed credential attainable in medicine today.

Dr. Georgios V. Georgakis is affiliated with S.U.N.Y Stony Brook.

Fellowship Experience

University of Pittsburgh Medical Center

Additional Information

Dr Georgakis is a Surgical Oncologist specializing in treatment and management of malignant and benign tumors of the gastrointestinal tract including liver, pancreas, esophagus, stomach, small bowel, appendix and colon, and peritoneal mesothelioma with standard open surgery as well as minimally-invasive (laparoscopic and robotic) surgical techniques when possible. He is focusing in regional perfusion therapies for treating late-stage and advanced cancers, including cytoreductive surgery with heated hyperthermic intraperitoneal chemotherapy (CRS-HIPEC).

Dr Georgakis received his MD and PhD from the University of Athens, Greece, and completed his General Surgery residency at the University of Connecticut. He completed a Surgical Oncology Fellowship at the University of Pittsburgh Medical Center and a cancer research fellowship at the University of Texas, MD Anderson Cancer Center. He joined the faculty of SUNY Stony Brook Cancer Center as an Assistant Professor in 2017.He is a member of the American Society for Clinical Oncology, the Society of Surgical Oncology, the American College of Surgeons, the Society for Immunotherapy for Cancer, the MD Anderson Alumni & Faculty Association,the Society of American Gastrointestinal and Endoscopic Surgeons, the American Association for Cancer Research, and the Americas Hepato-Pancreato-Biliary Association.

His laboratory research interests include animal modeling and new drug discovery for regional cancer therapies, including HIPEC, and their translation to clinical trials.